ICB RAG Maps Updated

Existing RAG (Red, Amber, Green) mapping has been updated to reflect the ICB ratings released in March 2025.

The update, carried out by Charlotte Mallindine, Pooja Gudka and Elly Wakeling, tracks the fluctuations in terms of SGLT2 Inhibitors and Finerenone and builds on an audit first presented at the RPG Conference 2024 by East and North Hertfordshire NHS Trust.

The RAG mapping, conducted in collaboration with UK Renal Pharmacy Group members, continues to track the formulary status of these medicines, which are recommended by NICE for treating chronic kidney disease (CKD).

The maps below depict the shifts which occurred in the status of Finerenone and Dapagliflozin between the audit presented in 2024, and the update released by Charlotte Mallindine, Pooja Gudka and Elly Wakeling, reflecting the March 2025 data. The original poster, as presented at the 2024 RPG Conference, can also be downloaded below.

Audit of the RAG rating of SGLT2 inhibitors and MRAs for Integrated Care Boards within England

Finerenone 2025 Map

Dapagliflozin 2025 Map